Chemoembolization in Conjunction with Bevacizumab: Preliminary Results

Giammaria Fiorentini, Donatella Sarti, Camillo Aliberti, Riccardo Carandina, Luca Mulazzani, Alessandro Felicioli, Stefano Guadagni

Research output: Contribution to journalArticle

Abstract

Transarterial chemoembolization is an effective, minimally invasive therapy that is widely used for treatment of unresectable colorectal cancer liver metastases (CRC-LM). However, chemoembolization induces a hypoxic microenvironment, which increases neoangiogenesis and may promote early progression. For this reason, transarterial chemoembolization efficacy may be improved by combining it with an angiogenesis inhibitor, such as bevacizumab. This report shows that transarterial chemoembolization with irinotecan-loaded polyethylene glycol embolics and bevacizumab therapy was effective and well tolerated by 6 patients with CRC-LM, resulting in a disease control rate of 83% and an overall improvement in quality of life.

Original languageEnglish
Pages (from-to)1236-1239
Number of pages4
JournalJournal of Vascular and Interventional Radiology
Volume29
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Chemoembolization in Conjunction with Bevacizumab: Preliminary Results'. Together they form a unique fingerprint.

  • Cite this

    Fiorentini, G., Sarti, D., Aliberti, C., Carandina, R., Mulazzani, L., Felicioli, A., & Guadagni, S. (2018). Chemoembolization in Conjunction with Bevacizumab: Preliminary Results. Journal of Vascular and Interventional Radiology, 29(9), 1236-1239. https://doi.org/10.1016/j.jvir.2018.04.022